ClinicalTrials.gg
RecruitingNCT07695545PROMETAUpdated Jul 13, 2026

A Study of Lipid Metabolism and Mitochondrial Function in Myeloid Cells and Total Aortic Tissue in Patients With Ascending Thoracic Aortic Aneurysm (ATA) and Bicuspid (BA) or Tricuspid (TA) Aortic Valves.

An observational study in Ascending Aortic Aneurysm, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

Ascending aortic aneurysms (AAAs) are serious conditions that can lead to aortic dissections or ruptures, carrying a high risk of mortality. Their pathophysiology is based on complex mechanisms involving inflammatory and metabolic processes, as well as alterations in mitochondrial function. The presence of a bicuspid aortic valve (BAV) or tricuspid aortic valve (TAV) significantly influences the progression and severity of aneurysms. Bicuspid aortic valve (BAV) patients often develop aortic aneurysms earlier, as early as age 40-50, whereas tricuspid aortic valve (TAV) patients generally present with a degenerative condition that appears later (after age 50). The objective of this study is to compare the inflammatory, metabolic, and transcriptomic signatures of myeloid cells and total aortic tissue between BAV and TAV patients. These analyses will help identify specific molecular mechanisms, potential biomarkers, and therapeutic targets. To ensure pathophysiological homogeneity, patients with aneurysms of genetic origin (Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, etc.) will be excluded.

02

Conditions studied

  • Ascending Aortic Aneurysm
03

In context

Aneurysm, Ascending Aorta

22 studies on the registry are indexed under Aneurysm, Ascending Aorta; 11 are open to participants now.

This study's planned enrollment of 50 is below the median of 140 across 10 observational studies indexed under Aneurysm, Ascending Aorta.

Browse Aneurysm, Ascending Aorta studies →

Lead sponsor

Centre Hospitalier Universitaire Dijon is the lead sponsor of 499 studies on the registry; 103 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with ascending aortic aneurysms

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals who have given their consent
  • Patients with an ascending aortic aneurysm for which surgical replacement is indicated
  • Age > 18 years
  • Scheduled surgery
  • Preoperative ultrasound confirmation of the heart valve architecture (bicuspid or tricuspid valve)

Exclusion criteria

Exclusion Criteria:

  • A person subject to a legal protective measure (guardianship, conservatorship)
  • A person subject to a judicial safeguard measure - A pregnant woman, a woman in labor, or a breastfeeding woman
  • Adults who are legally incapacitated or unable to give consent
  • Emergency surgical procedures
  • Patients with uncontrolled inflammatory or conditions
  • Patients with a history of recent acute infection (within the last 3 months or still undergoing treatment)
  • Patients with a condition requiring - Patients with a confirmed or suspected genetic aneurysm (Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, etc.)
  • Patients with a history of cardiac surgery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient with an ascending aortic aneurysm and a bicuspid aortic valve (BAV)

    Patient with an ascending aortic aneurysm and a bicuspid aortic valve (BAV)

    Procedure: Additional blood samples · Procedure: Collection of discarded ascending aortic tissue

  • Patient with an ascending aortic aneurysm and a tricuspid aortic valve (TAV)

    Patient with an ascending aortic aneurysm and a tricuspid aortic valve (TAV)

    Procedure: Additional blood samples · Procedure: Collection of discarded ascending aortic tissue

Interventions

  • ProcedureAdditional blood samples

    Additional blood sample are collected at the time of routine clinical blood sampling for recherche analyses.

  • ProcedureCollection of discarded ascending aortic tissue

    The aneurysmal portion of the ascending aorta (surgical specimen), which would otherwise be discarded, is collected for research purposes. No other tissue is collected, and the research protocol does not alter the surgical procedure.

06

What researchers measure

Primary outcomes

  1. Inflammatory, metabolic, and transcriptomic markers of myeloid cells and aortic tissue

    Time frame: At the time of surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Aug 2029, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartActual
Jun 28, 2026
Primary completionEst.
Aug 2029
CompletionEst.
Aug 2029
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07695545
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jun 28, 2026
Primary completion
Aug 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Jul 13, 2026

Study contacts

Comlan BLITTI
Contact
comlanmawuko.blitti@chu-dijon.fr
03.80.29.33.52 ext. +33

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion